Shilpa Medicare is locked its upper circuit limit at Rs. 939.10, up by 44.70 points or 5.00% from its previous closing of Rs. 894.40 on the BSE.
The scrip opened at Rs. 891.00 and has touched a high and low of Rs. 939.10 and Rs. 880.00 respectively. So far 17446 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 1 has touched a 52 week high of Rs. 1003.20 on 16-Jun-2025 and a 52 week low of Rs. 530.50 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 939.10 and Rs. 846.05 respectively. The current market cap of the company is Rs. 9153.23 crore.
The promoters holding in the company stood at 44.23%, while Institutions and Non-Institutions held 18.52% and 37.25% respectively.
Shilpa Medicare has received EIR with VAI (voluntary action indicated) classification for Unit VI, Dabaspet, Bengaluru, Karnataka, from U.S. Food and Drug Administration (USFDA). The GMP inspection was conducted from October 24-30, 2024. This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Oral Dissolving Films and Transdermal Systems.
The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia. This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: